Glad to see you're still around jacosa. Amazing how much trash the board gets littered with after big moves. No messages for days and now all this non-sense. It's no wonder the old shorts lost their shirts. Their ignorance is astounding. Can't say what will happen over the next few weeks but remaining catalysts are:
1) If Esbriet posts good Q1-2014 results then watch out. With the results of ASCEND, I would imagine IPF patients will be contacting their docs and asking to start Esbriet immediately. 6 more weeks until Q1 ends.
2) If BI's phase III data looks average, then even more advantage for Esbriet. BI recently started a new PIII trial with VERY SOFT end points; this usually signifies a drug that can't show any hard/objective benefit.
Some big ifs, but I think both scenarios above could play out in ITMN's favor. As for buyout, I think it's already priced in. Most likely suspects would be a company that already sells PAH drugs, maybe GILD or Acetilion.